European regulators on April 1 issued a conditional approval recommendation for the use of Johnson & Johnson's Darzalex in patients with blood cancer. The committee is awaiting more data from two ongoing studies.
EU Recommends Conditional Approval For Johnson & Johnson's Blood Cancer Drug Darzalex
Tech Times - 4 Apr 2016 03:47
European regulators on April 1 issued a conditional approval recommendation for the use of Johnson & Johnson's Darzalex in patients with blood cancer. The committee is awaiting more data from two ongoing studies.
Share this Article
Recommended